Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ganglioneuroblastoma × fludarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 33 Leukemia 26 Lymphoma, Non-Hodgkin 23 Lymphoma 22 Precursor Cell Lymphoblastic Leukemia-Lymphoma 21 Leukemia, Lymphocytic, Chronic, B-Cell 19 Recurrence 18 Myelodysplastic Syndromes 18 Hematologic Neoplasms 17 Melanoma 15 Neoplasm Metastasis 14 Lymphoma, B-Cell 14 Multiple Myeloma 12 Hodgkin Disease 11 Pancreatic Neoplasms 10 Lymphoma, Large B-Cell, Diffuse 10 Stomach Neoplasms 9 Ovarian Neoplasms 9 Breast Neoplasms 9 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8 Lymphoma, Mantle-Cell 7 Lymphoma, Follicular 7 Uterine Cervical Neoplasms 6 Neoplasms 6 Carcinoma, Non-Small-Cell Lung 6 Triple Negative Breast Neoplasms 5 Neoplasms, Plasma Cell 5 Burkitt Lymphoma 5 Myeloproliferative Disorders 4 Mesothelioma, Malignant 4

Interventions

Cyclophosphamide 2 sargramostim 1 iberdomide 1 fludarabine 1 dinutuximab 1 Topotecan 1 Magnetic Resonance Spectroscopy 1 Influenza Vaccines 1 Colony-Stimulating Factors 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07502287 2026-03-30

DUAL-NK-NB

Beijing Biotech

Phase 1/2 Recruiting

Neuroblastoma, Recurrence, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡